Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
Abstract Despite significant advancements in therapy of multiple myeloma (MM) over the past 20 years, most patients experience relapse, necessitating new treatment approaches. This study aims to compare the real-world effectiveness of lenalidomide (LEN)-based triplet therapies, specifically daratumu...
Saved in:
| Main Authors: | Jiri Minarik, Ludek Pour, Vojtech Latal, Tomas Jelinek, Jan Straub, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Martin Stork, Tomas Pika, Petra Krhovska, Tereza Popkova, Frantisek Sedlak, Ivan Spicka, Pavel Jindra, Vladimira Capounova, Vladimir Maisnar, Roman Hajek |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14087-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)